公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2016 | Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: Post hoc analyses of the randomized LUX-Lung 3 and 6 trials | CHIH-HSIN YANG ; Sequist L.V; Zhou C; Schuler M; Geater S.L; Mok T; Hu C.-P; Yamamoto N; Feng J; O'Byrne K; Lu S; Hirsh V; Huang Y; Sebastian M; Okamoto I; Dickgreber N; Shah R; Märten A; Massey D; Wind S; Wu Y.-L. | Annals of Oncology | 152 | 142 | |
2017 | EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: Analysis of LUX-Lung 3 and 6 | Wu Y.-L; Sequist L.V; Hu C.-P; Feng J; Lu S; Huang Y; Li W; Hou M; Schuler M; Mok T; Yamamoto N; O'Byrne K; Hirsh V; Gibson N; Massey D; Kim M; CHIH-HSIN YANG | British Journal of Cancer | 70 | 60 | |
2022 | Enhancing deep-UV emission at 234 nm by introducing a truncated pyramid AlN/GaN nanostructure with fine-Tuned multiple facets | Lu S; Jiang X; Wang Y; Huang K; Gao N; Cai D; Zhou Y; Yang C.C; Kang J; Zhang R.; CHIH-CHUNG YANG | Nanoscale | 8 | 7 | |
2019 | First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials | Schuler M; Paz-Ares L; Sequist L.V; Hirsh V; Lee K.H; Wu Y.-L; Lu S; Zhou C; Feng J; Ellis S.H; Samuelsen C.H; Tang W; Märten A; Ehrnrooth E; Park K; CHIH-HSIN YANG | Lung Cancer | 26 | 19 | |
2019 | First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression | Schuler M; Tan E.-H; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG ; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K. | Journal of Cancer Research and Clinical Oncology | 30 | 27 | |
2021 | Lipin 1 deficiency causes adult-onset myasthenia with motor neuron dysfunction in humans and neuromuscular junction defects in zebrafish | Lu S; YUNG-SHU KUAN et al. | Theranostics | 10 | ||
2016 | Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer | Lu S; Cheng Y; Zhou C.-C; Wang J; Chih-Hsin CHIH-HSIN YANG ; Zhang P.-H; Zhang X.-Q; Wang X; Orlando M; Wu Y.-L. | Clinical Lung Cancer | 10 | ||
2021 | One-class anomaly detection via novelty normalization | Wu J.-C; Lu S; Fuh C.-S; Liu T.-L.; CHIOU-SHANN FUH | Computer Vision and Image Understanding | |||
2019 | Pan-asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: A csco-esmo initiative endorsed by jsmo, ksmo, mos, sso and tos | Wu Y.-L; Planchard D; Lu S; Sun H; Yamamoto N; Kim D.-W; Tan D.S.W; CHIH-HSIN YANG ; Azrif M; Mitsudomi T; Park K; Soo R.A; Chang J.W.C; Alip A; Peters S; Douillard J.-Y. | Annals of Oncology | 209 | 174 | |
2018 | Phase II study of crizotinib in east asian patients with ROS1-positive advanced non–small-cell lung cancer | Wu Y.-L; CHIH-HSIN YANG ; Kim D.-W; Lu S; Zhou J; Seto T; Yang J.-J; Yamamoto N; Ahn M.-J; Takahashi T; Yamanaka T; Kemner A; Roychowdhury D; Paolini J; Usari T; Wilner K.D; Goto K. | Journal of Clinical Oncology | 240 | 183 | |
2017 | Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer) | Nokihara H; Lu S; Mok T.S.K; Nakagawa K; Yamamoto N; Shi Y.K; Zhang L; Soo R.A; CHIH-HSIN YANG ; Sugawara S; Nishio M; Takahashi T; Goto K; Chang J; Maemondo M; Ichinose Y; Cheng Y; Lim W.T; Morita S; Tamura T. | Annals of Oncology | 75 | 68 | |
2019 | Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer | Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot D.M; Tan E.-H; Tanaka H; Wu Y.-L; CHIH-HSIN YANG ; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N. | Lung Cancer | 26 | 26 |